HPS6

Across TCGA pan-cancer cohorts, HPS6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HPS6 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HPS6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HPS6 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where HPS6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.202	0.449	<.001	26	view →
UCEC	DFS	Tertile	II,III,IV	0.431	0.919	.013	22	view →
LUAD	OS	Quartile	III,IV	1.000	0.448	.037	4	view →
CCRCC	OS	Quartile	III,IV	0.851	1.000	.024	3	view →
GBM	DFS	Quartile	All	0.175	0.332	.043	2	view →
HNSC	OS	Median	II,III,IV	0.800	0.930	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HPS6–PDAC (DFS)

Open the PDAC breakdown →